S-NO-HSA application, e.g., has also been shown to have beneficial effects in wound healing [51], pulmonary hypertension [52], and an LPS model of septic shock in preclinical studies at doses up to 0.5 μmol/kg/h. The gene discussed is ALB; the disease is pulmonary arterial hypertension.